To evaluate the immune status in each melanoma subtype, we examined the number of total tumor-infiltrating lymphocytes (TILs), CD4<sup>+</sup> TILs, CD8<sup>+</sup> TILs, and tumor-infiltrating FoxP3<sup>+</sup> regulatory T cells (Tregs) to evaluate the immune status in each melanoma subtype using data from 137 patients with melanoma. This evidence concerns the gene CD4 and melanoma.